Arbutus Biopharma Corp
NASDAQ:ABUS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Kiwi Property Group Ltd
OTC:KWIPF
|
NZ |
|
Knight-Swift Transportation Holdings Inc
NYSE:KNX
|
US |
|
Wereldhave Belgium NV
XBRU:WEHB
|
BE |
|
APA Group
ASX:APA
|
AU |
|
L
|
Larq SA
WSE:LRQ
|
PL |
|
Canada Goose Holdings Inc
TSX:GOOS
|
CA |
|
Talbros Engineering Ltd
BSE:538987
|
IN |
Arbutus Biopharma Corp
EPS (Diluted)
Arbutus Biopharma Corp
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
EPS (Diluted)
$0
|
CAGR 3-Years
28%
|
CAGR 5-Years
30%
|
CAGR 10-Years
19%
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
EPS (Diluted)
-$1
|
CAGR 3-Years
32%
|
CAGR 5-Years
27%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Arbutus Biopharma Corp
Glance View
Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).
See Also
What is Arbutus Biopharma Corp's EPS (Diluted)?
EPS (Diluted)
-0.2
USD
Based on the financial report for Dec 31, 2025, Arbutus Biopharma Corp's EPS (Diluted) amounts to -0.2 USD.
What is Arbutus Biopharma Corp's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
19%
Over the last year, the EPS (Diluted) growth was 55%. The average annual EPS (Diluted) growth rates for Arbutus Biopharma Corp have been 28% over the past three years , 30% over the past five years , and 19% over the past ten years .
